Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKD 13.9
(17.0%)
HKD 13.9
(17.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 776.31 Million CNY | -18.61% |
| 2022 | 997.75 Million CNY | 29.09% |
| 2021 | 772.89 Million CNY | 41.23% |
| 2020 | 547.25 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 148.62 Million CNY | 0.0% |
| 2024 Q1 | 148.62 Million CNY | -26.99% |
| 2023 FY | 812.1 Million CNY | -18.61% |
| 2023 Q4 | 203.57 Million CNY | -2.33% |
| 2023 Q3 | 208.42 Million CNY | 8.4% |
| 2023 Q2 | 192.26 Million CNY | 0.0% |
| 2023 Q1 | 192.26 Million CNY | -24.81% |
| 2022 Q1 | 215.8 Million CNY | -6.94% |
| 2022 Q4 | 255.72 Million CNY | 0.0% |
| 2022 FY | 997.75 Million CNY | 29.09% |
| 2022 Q3 | 255.72 Million CNY | 18.5% |
| 2022 Q2 | 215.8 Million CNY | 0.0% |
| 2021 Q2 | 156.08 Million CNY | 0.0% |
| 2021 FY | 772.89 Million CNY | 41.23% |
| 2021 Q4 | 231.89 Million CNY | 0.0% |
| 2021 Q3 | 231.89 Million CNY | 48.57% |
| 2021 Q1 | 156.08 Million CNY | 0.0% |
| 2020 FY | 547.25 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | -138.831% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | -5.014% |